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CD16 is a physiologically essential Fcγ receptor III as either a single- pass 
transmembrane protein (CD16A) or as a glycosylated phosphatidylinositol (GPI) 
anchored protein (CD16B) on the surface of immune cells that have been implicated in 
many autoimmune and immune complex-mediated diseases.  Its functions include 
binding and clearing antibody (IgG) coated foreign pathogens, receptor-mediated 
phagocytosis, and triggering antibody dependent cellular cytotoxicity.  It is well 
established that these functions depend on protein-protein interaction between CD16 and 
the Fc domain of IgG.  However, the molecular details of CD16-IgG interactions are less 
well defined, but are essential to developing therapeutic compounds to treat many 
autoimmune and IC diseases.  Stable mammalian cell lines expressing wild-type CD16 
isoforms and site-specific mutants, including extracellular soluble fragments of CD16 
have been established.  Soluble forms of wild type CD16A and these CD16 mutants were 
expressed in a bacterial pathway in order to amass sufficient quantities for x-ray 
crystallographic studies.   
The soluble portions of wild-type CD16A and several site-specific CD16A and 
CD16B mutants were constructed by PCR amplification and ligation with a pET vector.  
The proteins were expressed in a prokaryotic pathway, BL21 AI, for 8-10 hours and lysed 
to obtain inclusion bodies. A hand-held sonicator was used to wash the inclusion bodies, 
while a Urea solution separated and dissolved the proteins.  The target proteins were then 
refolded by rapid dilution, concentrated with a stir cell, and purified.  Wild type sCD16A 
and four site specific mutants were constructed with good sequencing, while wild type 
 xii
sCD16A, sCD16A F176V, and sCD16A G147D were expressed and refolded to optimal 
levels.  X-ray crystallographic data has been collected from sCD16A F176V as a result of 
these studies and crystals are currently being grown from wild type sCD16A and 











With the prokaryotic expression and crystal growth of wild type soluble CD16A and 
soluble CD16 site specific mutants, X-ray crystallographic diffraction data can be 
collected and used to solve various CD16 extracellular structures, lending vital 
information to ongoing FcγR- IgG complex functional studies and identifying therapeutic 
schemes in treating autoimmune diseases.   
Specific Aims 
Specific Aim 1:  Construction and expression of wild type soluble CD16A along with 
site-specific mutants.  A prokaryotic expression system will be established to express 
several forms of soluble CD16 (extracellular portion of FcγRIII).  CD16 has two 
subtypes, A and B, while the B subtype has two polymorphic forms, CD16BNA1 and 
CD16BNA2.  Wild type sCD16A and its site-specific mutants, F176V and G147D, along 
with the same site-specific mutants for CD16BNA1 and CD16BNA2, will be expressed.  
The soluble form of membrane receptors is an excellent source for crystallization and 
subsequent determination of the ternary structure of a receptor.  Only the extracellular 
domain of the CD16 is involved in ligand binding, therefore only this portion of the 
molecule will be used as it should maintain is functioning ability.  The hydrophobic 
transmembrane domain will be bypassed using PCR.   
 The CD16 gene from pCDNA 3.1 vectors in E. coli bacterial cells (TOP 10 
Invitrogen) will be amplified by PCR from Trp-2 to Ser-211.  Primer development will 
create Nde-I and Not-I restriction enzyme sites and a stop codon (amino acid 211). PCR 
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amplification of the gene takes place, followed by the subsequent digestion (Nde-I and 
Not-I) and ligation with the new vector, pET 21a+ (Novagen).  pET 21a+ includes a C-
terminal His-tag sequence and a T7 tag.  TOP-10 (Invitrogen) E. coli cells will be used 
for long term storage of the new gene and vector combination.  Sequencing on the ligated 
structure is performed to check the accuracy of the previous steps.   
 The ligated soluble protein DNA and pET 21a+ vector are transformed into a 
BL21 expression pathway.  Protein is induced with IPTG, both alone and in combination 
with L-Arabinose depending on the BL21 pathway, for 6-10 hours.  The bacterial pellet is 
to be collected, lysed, and sonicated to obtain treated and washed inclusion bodies.    
 
Specific Aim 2:  Dissolve inclusion bodies, refold sCD16 protein, and obtain high purity.  
Soluble CD16 proteins are found almost exclusively in Inclusion Bodies after lysis [4, 5].  
A detergent is used to separate the inclusion bodies and dissolve the proteins.  Refolding 
agents are added and the detergent is removed to force proper folding.  Several refolding 
and concentrating methods are to be tested to find a high enough yield, 10mg/ml 
concentration of soluble CD16 protein, and a pure enough sample, greater than 90-95% 
according to SDS-PAGE.  Among the refolding techniques are rapid dilution injections, 
dialysis tubing, and sephadex columns with gradient buffers.  Among the concentration 
methods are stir cells, centrifuge concentrators, polyvinylpyrolidone powder, and dialysis 
tubing.  And among the purification techniques are washing steps, affinity 
chromatography, and size exclusion columns.  Sandwich ELISA will be used to confirm 
functional ability.   
 
Specific Aim 3:  Grow crystals and determine the crystal structure of sCD16 protein.  
Previous studies by Sondermann, et al [4], and Zhang, et al [5], established sCD16B 
crystallization techniques.  It is logical to start the sCD16A wild type crystal trials with a 
similar technique.  However, since crystallization techniques are hard to replicate, wide 
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screening kits should be used in order to cover all crystal solutions.  Upon crystal growth, 
the National Synchrotron Light Source can be used to collect diffraction data.  Structure 

















Background and Significance 
 
1.1 Role of FcγRs In Host Defense 
 Cellular receptors for the Fc domain of IgG antibodies, (FcγR), have a crucial role 
in the development of autoimmune diseases [9, 10, 11, 12].  These receptors link the 
bodys recognition of antigens with cellular responses [14].   FcγR are expressed by 
immune cells such as neutrophils, monocytes, and dendritic cells, which recognize and 
eliminate antibody-coated foreign objects.  This takes place through FcγR mediated 
process called ADCC, or antibody-dependent cellular cytotoxicity, and phagocytosis [8].  
FcγR can also be occupied by immune complexes, which then induces the secretion of 
inflammatory mediators and lymphokines [15].  Any error in this process, owing to faulty 
FcγR function, can cause a number of diseases and disorders. 
 FcγR has four classes (Figure 1) that belong to the IgG superfamily [13].  There is 
the high affinity receptor of FcγRI (CD64) which is about 70 kD, expressed on 
monocytes and tissue macrophages, and has a Kd of 10-8 for monomeric IgG [8, 13].  Its 
high affinity is partially due to its having three related immunoglobulin domains [18].  
Next are the low affinity receptors of FcγRII (CD32) and FcγRIII (CD16).  Their Kds 
for monomeric IgG is between 10-5 and 10-7 [13] as they have only two related 
immunoglobulin domains [18].  CD32 has a size of 40 kD [8] and is expressed on B cells, 
platelets, monocytes, macrophages, neutrophils, epithelial, and endothelial cells [16].  
There are three subtypes of CD32:  CD32A, CD32B, and CD32C.  The A and C subtypes 
are almost identical, with sequencing showing only a single amino acid difference [17], 
while subtype B is 93% identical to A [18].   
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 The third FcγR is FcγRIII, or CD16, and is a glycoprotein between 50- 70 kD.  It 
has two subtypes, CD16A and CD16B.  CD16A is mainly present on natural killer cells 
and T cells [13], while CD16B is expressed mainly on neutrophils [8].  Further, CD16B 
has two polymorphic forms, NA1 and NA2 [19].  The NA stands for neutrophil antigen.  
These two forms differ slightly in the membrane-distal Ig-like domain, which causes 
NA1 to bind immune complexed IgG3 more efficiently than NA2 [20].  NA1 also 
induces phagocytosis of particles opsonized with either IgG1 or IgG3 [19].  CD16A is 
polypeptide anchored, while CD16B is anchored to the cell surface via a C- terminus GPI 
moiety [8, 21].  Lastly, CD16 is also found in a soluble form [22, 23] from activated 
neutrophils that proteolytically cut off the soluble, or extracellular, portion of CD16 that 
leads to increased production of inflammation mediators.  And the fourth class is the 
recently published FcγRIV, from Ravetch and colleagues [75].  This receptor binds to 
IgG2a and IgG2b with intermediate affinity and its expression is limited to myeloid 
lineage cells [75].  Important binding domains in the FcγR-IgG complex will be 
discussed after Fc receptor structure papers are reviewed.  
 CD16A and CD16B also hold different signaling methods in the previously 
mentioned antibody-dependent cellular cytotoxicity [24].  CD16A utilizes an 
Immunoreceptor Tyrosine-based Activation Motif (ITAM) to aid in the signaling 
processing of activated natural killer cells, while CD16B, as previously mentioned, has a 
GPI anchor and lacks a signaling component [27].  This GPI anchor does not prevent 
signaling and plays an active role in Ca+2 mobilization and neutrophil degranulation [25].  
Also, CD32A can co-aggregate with CD16B and aid in triggering cytotoxicity although 
the cross-regulation of this process has not been completely solved [8, 25].  CD16As 
ITAM is negatively regulated by CD32B and its ITIM [26].  Another pathway that 
regulates CD16 is CD32A ligand-binding function, although this too has not been 
completely solved [8].      




Figure 1.  Human FcγR family of receptors [13].  FcγRIIC, FcγRIV are not shown.  
Figure from Fridman, et al., Immunology 2004.  Anchorage is accomplished by single 
pass polypeptide (α) or by Glycosyl Phosphatidylinositol (GPI). Associated signaling 
pathways are depicted by γ and ζ.  FcγRIIa and FcγRIIb have intrinsic signaling pathways 
that are incorporated in the α polypeptide anchor.  ITAM (activation) and ITIM 
(inhibitory) are the signaling pathways depicted.   
 
 It should be noted that polymorphisms exist in the FcγR family [19].  These 
changes in the structure have been shown to have an effect on receptor binding and have 
also shown to have an influence in immunotherapy.  The three receptors with notable 
polymorphisms are FcγRIIA (R131H), FcγRIIIA (V176F), and the two neutrophil antigen 
forms of FcγRIIIB previously mentioned.  The expression of the arginine at amino acid 
position 131 in CD32A, the valine in CD16A, and neutrophil antigen 1 in CD16B all 
increase efficiency of binding with IgG.  There are reports of less frequent 
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polymorphisms in all members of the FcR family and each has an effect on the biding 
function of the receptor.  Some polymorphisms, like CD16A V176F have been studied in 
an attempt to find a link to certain autoimmune diseases [19].  The V176F mutation in 
CD16 is involved in three of the six mutations that have been selected to be expressed in 
soluble form in this study. 
 As previously described, Fc receptors play a major role in our bodys immune 
responses and understanding the FcγR will only further aid our knowledge of 
autoimmune diseases and antibody-mediated immunotherapy.  There is much that is still 
not known about FcγR, such as the solved structures of all members of the family 
(including complex formation with IgG), which are important to understanding this 
family of receptors as it can be correlated to complimentary functional data.  These 
studies can discover and verify trends among the receptors, be used as a verification 
method to proposed renderings of structures, show amino acid locations, show both 
internal and external binding characteristics, and show other molecular structures that 
may be present.  Several groups have published research papers using x-ray 
crystallography as a method of solving the structures of FcγR [4, 5, 28, 29, 30].  
  
1.2 X-ray Crystallography Technology and History 
 X-ray crystallography was accidentally discovered almost 100 years ago when a 
German physicist, Max von Laue, directed an X-ray beam through a crystal and 
discovered a diffraction pattern [31].  A few years later, an Australian team of William 
Henry Bragg (father) and William Lawrence Bragg (son) won the Nobel Prize for 
Physics by using a mathematical method to analyze the diffraction data put forth by the 
X-ray.  This process, deemed X-ray crystallography soon grew in importance as X-ray 
diffraction patterns were used to determine numerous molecular models of biological and 
chemical formations. First used to determine atomic structures in biochemical materials, 
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the technique has grown to play a role in synthesizing medical chemicals, mineralogy, 
and in our case, protein structures.  X-ray crystallography of DNA, performed by 
Rosalind Franklin, played a large role in James Watson and Francis Cricks solution of 
the DNA double helix structure.  The first protein crystallized and solved was myoglobin 
from a sperm whale (1958) [32].   
 X-ray crystallography technology has improved vastly in the past 15 years, 
allowing for far superior resolution in solving proteins to the point that amino acids, 
solvents, sugars, and other structures can be readily determined.  In order to determine a 
protein structure, a large amount of pure protein must be developed and a crystal must 
form with the protein inside of it [32].  A vapor diffusion method was used for growing 
crystals in this project [79].  This method uses a closed chamber with a large reservoir 
with precipitant solution and a hanging drop above that is made of equal parts protein 
solution and the reservoir solution.  The precipitant level in the drop increases and may 
force crystals to form as a vapor reaction takes place, pulling the water out of the drop.   
 Once crystals are formed, an X-ray diffraction experiment is set up.  An X-ray 
source generates an X-ray beam that passes through the crystal and becomes diffracted.  
The X-ray beam is filtered by monochromators and/or mirrors, which create a more 
focused X-ray beam and a better pattern by lowering background interference [78].  The 
crystal itself is mounted on an apparatus that is rotational [77].  The diffraction pattern is 
recorded on the opposite side of the crystal and further analyzed in order to determine the 
structure.  This experiment will make use of molecular replacement software with a 
previously solved protein, sCD16BNA2, as a template.  After exposure, the crystal can be 
become damaged due to the onset of chemical reactions triggered by the beam.  Using a 
high power source like a Synchrotron will give better results before the crystal is too 
damaged to be accurate [78].  Proteins are asymmetric objects and are determined by 
examining the diffraction pattern and taking note of any symmetry and systemic absences 
[78].  This gives rise to space groups.  There are 230 possible space groups, but only 65 
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are possible due to the asymmetry.  Using space groups and molecular replacement, 
structures can be developed.  Resolution can also be improved by a method that rapidly 
cools the crystal to a temperature close to that of liquid nitrogen.  This process is called 
cryo-cooling [79].       
 The limiting step is usually the protein crystal development because the x-ray 
diffraction patterns tend to be weak, which can be offset by larger crystals containing 
high amounts of pure target protein with the crystal solvent (about 50%) [76].  Purity of 
the proteins allow for larger crystal growth as impurities in the solution can create 
precipitation, create conformation changes to the target protein, affect solubility, and alter 
solvent conditions to prevent crystals from ever forming.  The method is not sensitive 
enough to obtain a diffraction pattern from just one molecule of the protein but can obtain 
significant patterns when the starting protein solution is of the milligram per milliliter 
concentration [77].   
1.3 Structure Studies of the FcγR Family 
    The FcγR family has been undergoing crystallographic analysis by several 
groups [4, 5, 28, 29, 30].  These studies include the structures for FcεRIα (Garman and 
Wurzburg et al [33]), FcγRIIA (Maxwell et al [29]), FcγRIIB and FcγRIIIB (Sondermann 
et al [4, 30], and a second FcγRIIIB (Zhang and Sun et al [5]).  Results from the 
crystallographic analysis, combined with sequence analysis, show about 40% sequence 
similarity between these receptors, a general heart shaped form, and high interaction 
between the Ig domains [34].  These studies are major influences in this current project 
are described next. 
 FcεRIα is the high-affinity IgE receptor [34] and it is found on the surface of 
effector cells [28].  These effector cells are involved in several processes, including 
allergic responses, anaphylaxis and anti-parasitic immunity.  The receptor has a Kd of 10-
9 to 10-10 and is either a trimeric or tetrameric form [35].  Crystal structures of this 
 10
receptor were formed alone [28] and as a complex of IgE-Fc-FcεRIα [33].  Figures 2 and 
3 show these forms.  Garman first developed the receptor alone and then later bound to 
IgE-Fc, but needed to make residue substitutions to the IgE-Fc protein in order to 
improve the crystal qualities [35].  Insect cells were used to express wild type IgE-Fc, 
FcεRIα and a carbohydrate mutant, FcεRIα∆4-6, which lacks three of the seven wild type 
carbohydrate sites and was developed to improve crystal formations [35].  After the 
complex formed, vapor diffusion was used to form the crystal, which took 1 year to 
appear, before diffraction and modeling took place [36].  The complex made with wild 
type FcεRIα receptor had a limiting resolution of 4.5Å, while the carbohydrate mutant 
(∆4-6) showed a limiting resolution of 3.5Å [35].   
 The model for FcεRIα (Figures 2A and 3A) shows two, non-identical, tryptophan 
heavy binding sites for IgE-Fc.  These binding sites will be explained after the 
completion of the FcR structure review.  These tryptophans bind to prolines in the Fc-
fragment.  Site 1 shows two potential salt bridges and four potential hydrogen bond sites, 
while site 2 shows three potential hydrogen bond sites [28].  The FcεRIα- IgE-Fc binds in 
a 1 to 1 ratio due to conformational changes in the linker region of IgE-Fc upon complex 
formation and the blocking of further receptors by steric hindrance [35, 37].  Garman 
suggests that a kinetic scheme can be developed because there are two binding sites [35].  
He also calls attention to a study by Sayers, et al [38], that shows a biphasic 
disassociation rate for the two binding sites and that drug therapy could exploit this.  The 
study and model show good results, but the limiting resolution and mutations still dont 
give a perfect model.  Overall, the FcεRIα- IgE-Fc complex (Figure 2B) is very similar to 
the FcγRIIB-IgG-Fc interaction (Figure 3B) and is a valuable source of information for 







                       
 
 
Figure 2.  Solved crystal structures of FcεRIα, 2A, (MMDB #13689, PDB #1F2Q) [28], 
and of the FcεRIα- IgE-Fc complex, 2B, (MMDB # 13872, PDB #1F6A) [33], from 




            
 
Figure 3.  Side view of FcεRIα in ribbon form, 3A.  Binding residues are in stick form 
while strands are labeled [33].  Superposition of FcεRIα -IgE-Fc complex (beige) with 
FcγRIIB-IgG-Fc complex (green), 3B.  Arrows indicate domains used to superimpose 
complexes [33].  Figure from Garman, et al. (MMDB #14309, PDB #1FP5) [33].   
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 Kelley Maxwell (Biomolecular Research Institute) and Maree Powell (Austin 
Research Institute) produced the crystal structure and model for FcγRIIA in 1999 [29].  
Their study obtained a 2.0 Å resolution structure of the extracellular portion of CD32A 
(Figure 4a).  Human FcγRIIA was developed [39] by both mammalian and insect cell 
methods to form the appropriate crystals needed for trials.  There was difficulty in the 
interpretation of the diffraction data and modified phases used only 76% of the amino 
acid residues to start the solving process [29].  After several cycles of refitting the 
structure was finalized.  Even with the 2.0 Å resolution, the authors admit that some of 
the residues atomic positions cannot be considered totally reliable [29].  This in itself is 
reason enough to garner more attention to FcγR crystal studies.   
 Maxwell and Powells study showed several things about the CD32A structure.  
They calculated a 52° angle between the domains (D1 and D2) [29], which is similar to 
the previous FcεRI structure [28] and backed up by sequencing studies showing the 
conservation among the receptors [29].  The model also showed that D2 was the main 
ligand binding domain and had a two residue linker to D1.  This structure also had 
several potential hydrogen binding sites in its contact area.  Past research [40] using 
substitution mutations to define the binding region for IgG1 was repeated for IgG2 to 
confirm the main ligand binding region [29].  An exposed Arginine at position 134 in D2 
is the reason that the receptor is shown to bind IgG1 and IgG2 differently [29].  One of 
the main features that this study found was CD32A formed dimers (Figure 4b) in the 
crystal structure that were very similar to those found in the VLVH structures (light and 
heavy chains of the antibody variable domain) [41], although it is a tighter pack.  The 
study predicts that this dimer formation is involved in the binding of IgG and that the 
other CD32 subunits are similar due to the similarity of the extra-cellular sequencing 
[29].  The results of this study are in contrast with Peter Sondermanns findings [30] 






Figure 4.  FcγRIIA structure, 4A, in ribbon form.  Strands are lettered A-G while D1 
domain is blue and D2 domain is green with an angle of 52° between them.  Ribbon 
diagram of an FcγRIIA dimmer, 4B.  Figure from Maxwell, et al. (MMDB #13259, PDB 
#1FCG) [29]. 
  
 Peter Sondermann and colleagues solved the crystal structure of FcγRIIB [30] to a 
limiting resolution of 1.7Å in 1999.  The author developed recombinant soluble 
(extracellular) human CD32B and expressed the protein in E. coli cells.  An Inclusion 
Body method, described in detail later, is prepared by a sonication method from 
overexpressed extracellular CD32B [42].  After dissolving the inclusion bodies and 
refolding the proteins, crystals were formed using a vapor diffusion method.  Diffraction 
data was collected and an electron density map was formed to 2.1Å and later to 1.7Å with 
several model refinements [30].  
 Sondermanns CD32B (Figure 5) structure is made of two domains forming a 
heart shaped sandwich with a 70° angle between the two domains [30].  Three different 
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spacing groups resulted in the same structure, confirming its reliability.  However, all 
three groups showed disorder of the last nine residues of the polypeptide chain [30].  The 
structure also found three potential N-glycosylation sites:  N61, N142, and N135.  The 
study suggests from further computer modeling that two CD16B receptors bind to a 
single antibody forming a 2 to1 stoichiometry.  It is also suggested that this model creates 
an upright complex allowing for further binding that would help explain the signaling 
capabilities of the receptor.  This is obviously in disagreement with the CD32A crystal 




Figure 5.   Structure of human sFcγRIIB in ribbon form.  Red loops are interaction sites 
for IgG binding.  Ball and stick formations are key residues for IgG binding and the 
disulfide bridge.  Green Balls are potential N-glycosylation sites.  Figure from 
Sondermann, et al. (MMDB #12664, PDB #2FCB) [30].   
   
  
 The final crystal structure studies and the most relevant for our project are Peter 
Sondermann, et al. [4], and Peter Sun, et al. [5].  These recently published papers report 
the crystal structures of FcγIIIB bound in a 1 to 1 complex with human IgG1 Fc.  
Sondermann was able to show the bound structure at a 3.2 Å limiting resolution (Figure 
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6A and 6B).  Upon the binding of sCD16B, hFc1 undergoes a structural reorganization 
(Figure 7).  Cγ2 moves away from Cγ3 upon this reorganization, along with a similarity 
between the FcγRs and the Proline sandwich being the primary binding motive in FcR- 
Ig complexes, provide Sondermann with a proposed mechanism for an allosteric 
interaction between FcRns and FcγRs using antibodies.  The two Cγ2 domains change 
differently, while Cγ3 remains relatively unchanged during this reaction.  Pro 329, an 
amino acid that is involved in the proline sandwich, moves Cγ2-B a further distance 
away than Cγ2-A.  The sCD16B also undergoes a significant change upon the binding 
furthering his mechanism.  Sondermann found that the interdomain angle increased 10°, 
from 70° to 80°.  There is also a side chain, Trp 95, which comes into contact with Tyr 14 
(sFcγII numbering system).  The author also goes into the interaction of the amino acids 
involved in the binding region and the possible van der Waals interactions and hydrogen 
bonding between them.  This seems to be a limiting factor of the study.  The limiting 
resolution of 3.2Å seems to be insufficient for finding these interactions with enough 
certainty.  Also, Sondermann only used sCD16BNA2 in his experiments and there are two 
forms of CD16B and one for CD16A.    
 
                        
 
Figure 6.  Structure of sCD16B in two forms.  sCD16B, 6A, (MMDB #14218, PDB 
#1E4J) [4, 71].  Stereo ribbon structure of sCD16B, 6B, with IgG contact residues in ball 
and stick formation.  Green contacts Cγ2-B while magenta contacts Cγ2-A.  Large balls 
(blue) are potential glycosylation sites and disulfide bridge is yellow.  Figure B from 
Sondermann, et al. [18]. 
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Figure 7.  The structure of the sFcγRIII-hFc1 complex in the vertical view, a, and in the 
90° rotated side view, b.  Ball and stick figures represent the proline sandwich while 
larger blue spheres exhibit glycosylation sites [4].  Figures created by MOLSCRIPT [72].  





 Peter Sun and colleagues [5] focused more on the extracellular portion of the 
sCD16B molecule (Figure 8) than Sondermanns paper did.  The authors, as the 
previously mentioned paper, showed the conservation of important regions throughout 
the FcγRs, which demonstrates the importance of solving a possible mechanism for these 
molecules.  This paper solved the crystal form of the sCD16B to a 2.3 Å limiting 
resolution using a multi-wavelength anomalous dispersion method.  The authors were 
able to refine the model to 1.8 Å resolution using additional techniques (Figure 8A).  
However, the authors seemed to have used a symmetry method that ended up taking 
away from the completeness of the molecule and calling into question the exactness of 
the actual form of sCD16B.  Zhang et al. also found the interdomain hinge angle to be 
50° which is far smaller than the 70° pre-complex angle reported by Sondermann et al.  
They noted previous discrepancies of reports of the domain angle of FcγIIA and FcγIIB 
[6, 7].  These angles were between 52° and 70° are attributed to using different 
algorithms in solving the structure.  Zhang et al. [5] tried to help explain the smaller angle 
by Domain 1 and Domain 2 being tightly packed together from interdomain interactions, 
i.e., van derWaals and hydrogen bonding (Figure 8B).  Also, he mentions that a bound 
phosphate ion was found in the hinge region on the second sCD16B molecule and that it 
has a role in the angle differences (Figure 8D).  Peter Sun and colleagues showed further 
detail than that of Peter Sondermann et al., but both studies need a better resolution in 






Figure 8.  Structure of FcγRIII [5] created by MOLSCRIPT [72].  A, FcγRIIIs (ribbon 
form) binding loops are red, D1 domain is blue, D2 domain is green.  B, KIRs domain 
orientation (ribbon form) resembling FcγRIII.  C, FcγRIIIs (ribbon form) interdomain 
region focusing on the packing domains (dark blue and green).  Residues and domains 
are labeled in the figure.  D, Asymmetric unit containing superimposed molecules A and 
B of FcγRIII.  Figure from Zhang, et al. (MMDB #14531, PDB #1FNL) [5].           
 
  
Figure 9.  FcR structures superimposed [18].  Disulphide bridges in yellow.  The color of 
the FcR name is the color of the structure.  Figure from Sondermann, et al. (PDB #s 
1FCG, 2FCB, 1FNL, 1EFJ, 1F6A) [18]. 
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 Using the solved sCD16BNA2-IgG complex as a template, Sondermann and 
colleagues [18] proposed that the FcγR-IgG interactions are conserved throughout the 
FcR family.  There are three main regions of the IgG molecule that FcR interacts with.  
They include the exposed proline at amino acid 329, the Cγ2-A region, and the Cγ2-B 
region (Figure 7).  The binding domains of each member of the FcR family that interact 
with these three IgG regions are conserved in location but not necessarily in sequence.  
The binding domains for FcR are located in the B/C, C/E, and F/G loops.  The C strand 
also contains important residues.  These regions are shown in Figures 2 through 9.  The 
binding residues for FcR are as follows.  Trp 87 and Trp 110 are the main binding 
residues for CD16, CD32, CD64, and FcεRIα.  They bind the antibodys Pro329 making 
a proline sandwich.  The residue at amino acid position 155 is responsible for binding 
to the Leu235 of IgG.  This interaction is not conserved throughout the family.  Position 
155 is a solvent exposed hydrophobic residue in CD16 and CD32 and leads these 
receptors to a low affinity interaction.  CD64 has a more pronounced hydrophobic 
interaction with Leu235 by using tyrosine and tryptophan, which accounts for its higher 
affinity.  Leu235 is replaced by a proline in IgE, which interacts with Trp 156 and Leu 
158 residues of FcεRIα accounting for its higher affinity. 
 CD16 and CD32 have additional residues that alter the binding of Leu235.  CD16 
has three histidine residues that contact residues 234-238 of the Fc-fragment.  His131 and 
His 132 are part of the C/E loop while His116 is part of the C strand.  These residues 
come into contact with Leu235 and lower the binding affinity.  In CD32, the histidine 
residues are replaced with smaller residues which would allow the Fc-fragment to bind 
closer to the receptor if not for the arginine at residue 131.  This residue lowers the 
affinity of CD32.  The final important residue is at position 129.  This is tyrosine in 
CD16 but may be phenylalanine in the other Fc receptors.  It makes multiple contacts 
with the Fc-fragment and is forces the receptor to tightly bind to the hinge region.                
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 The previously mentioned studies have gathered a large amount of information on 
the FcR family of receptors.  Figure 10 shows a sequencing study of all the wild types in 
the group and along with the gathered structure data, show conserved regions and 
residues that are involved in the functional binding [4].  The extracellular domains are 
also similar enough in 3-dimensional form to create binding schemes and motifs for the 
entire family.  Of particular interest are the interactions between Fc- gamma receptor III 
(FcγIII or CD16) and IgG antibodies.  A large amount of functional studies exist 
compared to the structure studies.  However, much is to be learned about the functional 
characteristics of the FcR family.  To have completely comprehensive functional 
analysis, high resolution crystal structures of CD16 are needed to help understand the 
structure-function relationship.  The CD16A structure has not been solved yet and its 
addition would only strengthen the studies of this family.  Previous studies have focused 
on crystal studies of the CD16BNA2- IgG Fc complex [4, 5].   
 This study will focus on the soluble form of CD16A and several site-specific 
mutations located in the interfacial region of the CD16BNA2- IgG Fc complex, which may 
change the form of the structure and/or its binding capabilities.  This information could 
lead researchers to a better understanding of the FcR family and improved methods to 
fight autoimmune disease, including drug development targeting these receptors.  With 
improvements in crystallography and prokaryotic expression pathways, the CD16A 
structure can be solved along with CD16A and CD16B site specific mutants.  Resolving 
all previous structures to a more definite level, both alone and in complex, with a better 
limiting resolution is also of importance.  Finally, carbohydrates and other effects need to 
be included in these studies in the future as they play an important role in the capabilities 
and structure of the FcR family.  Typically, they are absent from these studies due to a 
prokaryotic expression systems lack of post-translational modifications when expressing 
mammalian proteins.  Insect cell expression pathways have some post-translation 











Figure 10.  Sequence alignment of the FcR family [4] created by ALSCRIPT [73].  
Magenta depicts conserved cysteines.  Potential glycosylation sites are in blue.  Orange 
depicts identical residues in the first domain, while those identical in the second domain 
are pink and those identical in both are green.  Contact between domains by way of 
residue side chains are depicted in red arrows, while blue arrows are binding contact to 















MATERIALS AND METHODS 
  
2.1 Construction of the Soluble CD16 Gene 
 DNA for wild type CD16A [43] and six site specific CD16A and CD16B mutants 
were obtained from Dr. Torsten Witte in E. coli cells (Invitrogens TOP 10) with pcDNA 
3.1 vectors.  The site specific mutants included were sCD16A F176V, sCD16A G147D, 
CD16BNA2 V176F, CD16BNA2 D147G, sCD16 BNA1 V176F, and sCD16BNA1 D147G.  
Cultures were formed from these samples and a portion of each cell lines pellet was 
diluted in fresh liquid broth and grown at 37° C on agar plates with Ampicillin (100 
µg/ml concentration) for colony selection.  Selected colonies were grown overnight in 5 
ml of liquid broth with Ampicillin at 37°C.  A Qiagen Quickspin Miniprep Kit was used 
to obtain purified gene and vector DNA for all 7 CD16 protein cell lines.  Restriction 
digestion and gel electrophoresis were used to verify results [43].   
 Primers were developed [50] to insert a stop codon after amino acid Ser-211, as 
well as two restriction enzyme sites, Not I and Nde I.  The forward primer is named 
CD16extFP.  The 5 to 3 sequence is TGTGGCCATATGTGGCAGCTGCTCCTCCCA 
(start codon is underlined and the Nde-I site is in bold).  The reverse primer is named 
CD16RPextnotI.  The 5 to 3 sequence is CCCAGCGGCCGCGAATTATGAGATG 
GTTGACACTGCCAA (stop codon is underlined and the Not-I site is in bold).  Once in 
place, the new gene will now produce the soluble portion (extracellular) of the CD16 
protein from amino acid 2 to amino acid 211.   
 The soluble portions of all 7 CD16 proteins were replicated using Polymerase 
Chain Reaction (PCR) [50].  This reaction uses heating and cooling to open up the DNA 
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and primers along with polymerase to target a portion of DNA and replicate it.  The 
target DNA will be replicated exponentially due to repeated heating and cooling steps.  
The setup of the PCR reaction is as follows.  Each individual reaction has 10 µl of 10x 
PCR buffer (High fidelity grade- Invitrogen), 1.5 µl of forward primer, 1.5 µl of reverse 
primer, 10 µl of template DNA (1 to 4 ratio of DNA to water), 1 µl of dNTP, 0.75 µl of 
Platinum Taq Polymerase Hifi (Invitrogen), 10 µl of MgCl2, and 65.25 µl of sterile 
distilled water.  PCR products for all seven proteins were purified in a PCR purification 
kit from Qiagen (Qiaquick PCR Purification Kit) [66].   
 The soluble proteins were ligated to a new vector, pET-21a+ (Novagen) [50].  
The new vector and the soluble proteins are first digested with Nde-I and Not-I (Figure 
11) [54].  This reaction contains 10 µl of purified PCR product, 6 µl of sterile distilled 
water, 2 µl React 3 buffer (Invitrogen), 1 µl of Not-I (Invitrogen), and 1 µl of Nde-I 
(Invitrogen).  The solution is mixed in a microcentrifuge tube and incubated in a 37°C 
water bath for 2 hours.  An additional tube is set up that includes 10 µl of pET vector in 
place of the purified PCR products.   
 A 1.2 % low melting point agarose gel (Sigma) with Ethidium Bromide (3 µl per 
100 ml) was made with 20 µl wells and loaded with the digested products [51].  Gel 
electrophoresis was run to separate the digested products through the agarose gel.  The 
appropriate soluble protein and pET vector bands were cut out using a UV light and a 
razor blade.  A Qiagen Gel Extraction Kit was used to dissolve the agarose gel and purify 
the DNA [52, 53]. 
 A Rapid DNA Ligation Kit (Roche) was used to ligate the purified and digested 
soluble proteins with the purified and digested pET vector (Figure 11) [54, 55].  The 
protocol includes creating a solution of 3 µl of the insert, 1.5 µl of the vector arms, and 
5.5 µl of 1x DNA Dilution Buffer.  10 µl T4 DNA Ligation Buffer (2x concentration) and 
1 µl T4 DNA Ligase, was supplemented with the previous solution and incubated for 5 
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minutes at 15- 25°C.  Solutions were stored overnight at -20°C or used right away in a 
transformation experiment.  4 µl was the typical amount for packaging.   
 
 
Figure 11.  Construction of soluble CD16 gene and insertion into the pET 21a+ vector.   
 
 Transformation into TOP10 E. coli cells (Invitrogen) was performed next in order 
to check the success of the previous steps and for long term storage of cells [54].  4 µl of 
ligation solution was used in the transformation process.  The protocol is as follows [58].  
One 50 µl vial of competent cells was thawed on ice per ligation reaction product.  4 µl of 
centrifuged ligation reaction product solution was added to the competent cells and mixed 
by tapping gently.  The mixture incubated on ice for 30 minutes.  The solution was heat-
shocked for exactly 30 seconds in a 42°C water bath.  The vial containing the mixture 
was stored on ice and 250 µl of SOC medium (growing medium included in the 
Invitrogen kit, pre-warmed to 37°C) was added to the solution.  The vial was placed on 
its side in a 37°C shaker and incubated for 1 hour at 225 rpm.  50 µl of incubated solution 
was spread on agar plates containing Ampicillin (100 µg/ml).  The plates were inverted 
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and grown overnight at 37°C.  Colonies were selected (minimum of 5 per sCD16 DNA 
sample) and grown in 5 ml of liquid broth overnight at 37°C at 225 rpm [54].   
 Purified DNA was obtained by using a QIAprep Miniprep Kit [57] on 1 ml 
samples of the overnight growth in the previous experiment [54].  This DNA was used to 
confirm the success of the PCR, ligation, and transformation experiments.  An enzyme 
digestion was performed on 10 µl of the miniprep product, as previously described, using 
Not-I and Nde-I [54].  After the completion of this experiment, gel electrophoresis was 
carried out on a 1% agarose gel with EtBr to separate the DNA fragments [54].  A band 
at approximately 674 base pairs confirmed the correct restriction enzyme placement, as 
well as the correct inclusion in the pET vector.  A portion of the miniprep, both primers, 
and the vector were sent off to an outside sequencing lab, which confirmed that the 
protein was in sequential order.   
 After proper sequence confirmation, another transformation experiment was 
performed with cells that contained the proper expression pathway.  Since a pET vector 
was being used, Invitrogens BL-21 AI One Shot E. coli cells were used with the 
identical protocol as the previous transformation experiment [54, 56, 58].  Colonies were 
again selected and grown overnight at 37°C and 225 rpm.  Proper transformation was 
verified by Miniprep DNA purification, restriction digestion, and gel electrophoresis.  An 
alternative expression pathway, Stratagenes BL-21 RIPL [59] was also used when the 
Invitrogen pathway did not yield high expression for some of the mutants after numerous 
expression experiments were attempted.  The transformation protocol is identical to 
Invitrogens TOP10 One Shot tubes and was carried out accordingly [54, 56]. 
 
2.2 Expression of sCD16 proteins 
 The wild type sCD16A was used to establish a basis for expression conditions in 
both pathways, BL21-AI and BL21 RIPL, as optimal expression conditions are different 
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for every protein [67].  Both pathways [56, 59] have almost identical protocols for 
expression [4, 5, 56, 59] with Invitrogens BL-21 AI pathway having one additional 
reagent used to turn on the induction pathway.  Seed cells were grown overnight (liquid 
broth inoculated with cells from each pathway grown at 32°C and 225 rpm for 12-16 
hours) in order to have fresh cultures for expression experiments [54].  Seed cells were 
diluted with fresh liquid broth (1 to 20 dilution) and grown until the optical density at 600 
nm reads 0.4, signifying that the cells were in log phase, which was the standard point for 
bacterial induction.  To induce sCD16 production, .2% Arabinose and 1 mM IPTG were 
added to the vessel containing BL21-AI [56].  The vessel containing BL-21 RIPL 
received only 1 mM IPTG [59].  After 6 or more hours of incubation, each pathways 
cells were then spun down at 6,000 rpm and the pellets were collected and the cells lysed.  
Soluble CD16 proteins were found exclusively in inclusion bodies [4, 5, 50], which were 
treated, washed, and dissolved to check the protein levels and prepare for refolding.  The 
Inclusion Body Treatment protocol will be in the following section. 
 After BL21-AI was found to be the preferred pathway (discussed in the results 
section), more induction experiments were performed in order to fine tune the process 
and find optimal conditions.  Seed cells, with wild type sCD16A in BL21-AI pathway, 
were grown overnight and diluted with 50 ml fresh liquid broth in each vessel (wich100 
µg/ml Ampicillin concentration) and incubated at 37°C and 225 rpm [54].  The cultures 
were then grown to multiple Optical Density 600 nm levels, which included 0.4, 1.0, and 
1.5 [1, 2, 56].  When the culture reached its appropriate level, 0.2% Arabinose and 1 mM 
IPTG were added to turn on the induction pathway [56].  Each Optical Density level was 
grown for multiple durations ranging 6-14 hours [1, 2, 56].  All 15 cultures were spun 
down and their pellets lysed.  The inclusion bodies [1, 2] were treated, washed, and 
separated in a polyacrylamide gel after SDS-PAGE for analysis.  Gel electrophoresis [51, 
54] was run at 200 volts for 1 hour in either a 10% or 12% Tris-HCl polyacrylamide gel 
 27
(50 µl wells) from Bio-Rad.  Coomassie blue stain and Western Blot [51, 54] was 
performed on the gels to determine which starting conditions worked the best.   
 Coomassie Blue staining protocol is as follows [54].  Polyacrylamide gel was 
soaked in Fixing solution (50% methanol, 40% water, 10% Acetic Acid) for 90 minutes 
upon completion of gel electrophoresis.  The gel was then soaked in Coomassie Brilliant 
Blue Stain (45% methanol, 45% water, 10% Acetic Acid, 1g per 100 ml Coomassie 
Brilliant Blue powder) for 3 to 4 hours.  Finally, the gel was soaked in a Destaining 
Solution (30% methanol, 10% Acetic Acid, 60 % water) until background became clear 
and bands were visible.  
 Western Blot protocol is as follows [51, 54].  Upon completion of gel 
electrophoresis, a semi-dry blotter was used to transfer proteins from the gel to a nitro-
cellulose membrane.  A semi-dry blotter used a sandwich made up of 3 sheets of filter 
paper, then the gel, then the nitro-cellulose membrane, then three more sheets of filter 
paper.  The filter paper and membrane were cut to the same size as the gel and soaked in 
Transfer Buffer (25mM Tris buffer, .2M Glycine, 20% Methanol) for 15 minutes before 
the semi-dry blotter was run for 45 minutes at 90 mA.  After completion of the protein 
transfer, the membrane was dried for 1 hour and then blocked by soaking it in 5% non-
dairy milk powder (diluted in 1x TTBS buffer) overnight at 4°C.  The membrane was 
washed in fresh 1x TTBS buffer three times (15, 5, and 5 minutes).  Primary antibody (5 
µg/ml concentration) was diluted in 1x TTBS buffer.  The primary antibody used for 
sCD16 in the western blot was the anit-CD16 monoclonal antibody, 214.1.  The 
membrane was soaked in this solution for 1 hour at room temperature.  The membrane 
was washed three times again upon completion.  A secondary antibody, goat anti mouse, 
was diluted in 1x TTBS buffer (1 to 1000 dilution).  The membrane was now incubated 
in this solution for 1 hour at room temperature.  The membrane was washed, again, with 
fresh 1x TTBS buffer upon the completion of incubation.  Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare) was used to prepare the membrane for band 
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development.  The membrane was soaked in the Detection Reagent for 60 seconds and 
then placed with a sheet of unexposed film in an x-ray cassette.  X-ray exposure time 
varied.  A typical time for this experiment was 30 seconds prior to developing.   
  2.3 Obtaining and Treating sCD16 Inclusion Bodies 
 After optimizing the expression conditions, the wild type sCD16A and the site 
specific mutants were expressed on a larger scale.  After proteins were expressed, the 
culture was spun down and its pellet collected for inclusion body treatment [1, 2].  The 
pellet was washed with 1x PBS and re-spun.  The following protocol was based on the 
collected pellets of 6 L of starting culture.  The pellet was resuspended in 60 ml of 
Resuspension Buffer, or Lysis Buffer.  This buffer included 50 mM Tris-HCl (pH 8.0), 
100 mM NaCl, 5 mM EDTA, 0.1% NaN3, 0.5% Triton X100, 0.1 mM PMSF, and 1 mM 
DTT [1].  The pellet was dispersed in this solution and a stir bar was used to keep the 
solution flowing.  Next, 1.2 ml of 100 mg/ml lysozyme, 300 µl of 1.0 M MgCl2, and 1.0 
ml of 2 mg/ml Dnase I were added to the solution and left to stir for 30 minutes [2].   
 Following the resuspension steps, a sonicator was used to send sonic waves 
throughout the solution [1, 2].  The solution was kept on ice as the temperature would 
increase the longer the sonic waves were sent into the liquid.  There were five rounds of 
sonication.  During each round, the solution was sonicated, on high setting, for 9 minutes 
total.  These 9 minutes were broken up into 90 second intervals of continuous sonication 
allowing the solution to cool in between each interval [2].  After each round, the solution 
was centrifuged at 12,000 rpm.  The pellet was resuspended in fresh Resuspension Buffer 
and another round of sonication commenced.  The supernatants were saved for future 
analysis.  After the fifth round, the pellet formed after centrifugation was resuspended in 
Final Wash Solution.  The Final Wash Solution contained 50 mM Tris-HCl (pH 8.0), 100 
mM NaCl, 5 mM EDTA, and 0.1% NaN3.  The solution then underwent one more round 
of sonication and centrifugation.  An alternate sonication technique that was attempted 
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consisted of shorter bursts of sonication waves (30 second intervals rather than 90 
seconds) in order to keep the temperature of the solution to a minimum but was 
discontinued when inclusion bodies were not being washed to an optimal level (discussed 
in the results section) [1].       
 The pellet was made up entirely of washed inclusion bodies, which were 
dissolved so that refolding experiments could take place.  The inclusion bodies were 
dispersed in a Urea solution [1, 2].  The Urea solution contained 100 mM Tris (pH 8.0), 
50 mM Glycine, 8.5 M Urea, 5 mM GSSH, and 0.5 mM GSSG.  Approximately 100 ml 
of Urea solution were used for every 2 liters of starting culture.  After dispersing the 
pellet, the inclusion bodies were dissolved overnight using a stir bar at 4°C.  SDS-PAGE, 
followed by gel electrophoresis and a coomassie blue stain, were performed the following 
day on the dissolved inclusion bodies and the saved supernatants from the sonication 
steps to check protein purity.  Protein concentration in the Inclusion Bodies was 
estimated by UV scan.  Dissolved inclusion bodies were then used in refolding 
experiments with excess frozen for storage [1, 2]. 
 
2.4 Refolding and Concentrating sCD16 Protein From Dissolved Inclusion Bodies  
 Refolding of sCD16 was accomplished by a rapid dilution injection [3, 70] of 100 
mg of inclusion bodies into 1 liter of Refolding Buffer [3].  The Refolding Buffer 
included .4 M L- Arginine, .1 M Tris, 5 mM GSSH, .5 mM GSSG, .2 M PMSF (pH 8.3).  
The buffer was first chilled to 4°C and then an injection of equal volume dissolved 
inclusion bodies (Urea solution) and Injection Buffer (3 M Guanadine-HCL, 10 mM 
Sodium Acetate, 100 mM EDTA), equal to 50 mg of protein, was injected into the 
Refolding Buffer as close to the stirring bar as possible [3].  Stirring continued overnight 
and a second identical injection was given to the buffer the following morning.  Stirring 
continued another twenty-four hours, at which time the protein has finished refolding.   
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 Once the proteins have refolded, the solution was concentrated to a lower volume 
using an Amicon stir cell (Millipore) with a 10 kD NMWL Ultracel Amicon 
UltrafiltrationDisc membrane (Millipore) [4].  Once the solution was concentrated down 
below 50 ml, then 10 mM Tris or 1x PBS was added to dilute all refolding agents in the 
solution.  After appropriate washing was finished, the solution was transferred to Pierce 
iCON Concentrator Tubes (9 kD NMWL filter) for completion of concentration to a 
volume between 1-10 ml.  Centrifugation was carried out at 3,000 rmp (4°C) after 
washing the storage glycerin out of membrane with sdH2O [60].  Concentration was 
carried out to preference, about 3 ml in this case.  Refolded protein solution was 
transferred to a micro centrifuge tube and spun down to rid the solution of all 
precipitation and aggregates [1].  The final solution was tested for purity by SDS-PAGE, 
for concentration by Micro BCA Protein Assay Kit (Pierce) [54, 61], and for 
functionality by Sandwich ELISA [51, 54]. 
 Alternate refolding techniques attempted included a dialysis technique and a size 
exclusion column with a Urea gradient [70].  Both techniques used the same protein 
expression and inclusion bodies treatment protocols.  The dialysis method [1] involved 
using SnakeSkin Pleated Dialysis Tubing (Pierce, 3500 MWCO) [62] to slowly lower the 
Urea concentration, which aids in increasing the yield of refolding [70].  The refolding 
buffer in this protocol included 0.1 M Tris, 0.4 M L- Arginine, 1 mM EDTA, 1 µg/ml 
Leupeptin, 1  µg/ml pepstatin, 0.2 mM PMSF, and a particular amount of Urea.  The 
amount of Urea decreased in each step.  The first buffer had 4.0 M Urea, followed by 2.0, 
1.0, 0.5, and 0.0 M (pH 8.0).  The inclusion bodies were added to the dialysis tubing 
which was clipped or tied off.  The tubing and proteins were then submerged into 
refolding buffer that was stirring to start the dialysis process.  Dialysis for each step 
continued for 24 hours.  After the Urea was taken out of the protein buffer and the 
proteins were refolded, the solution continued to dialyze against a 1 to 4 ratio of refolding 
buffer (0M) to water for 24 hours.  Next, the refolded protein solution was dialyzed 
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against a storage buffer for 24 hours.  This protocol suggested a PNEA buffer (25 mM 
PIPES, 150 mM NaCl, 1mM EDTA and 0.02% NaN3) for the storage buffer [1].   
 Another refolding method attempted involved the use of a size exclusion column 
made of Amersham Sephadex beads and a gradient to drive refolding [70].  The protocol 
for this experiment included the following steps [63, 64].  A chromatography column was 
packed with Sephadex G-50 beads (1.0 cm x 30 cm) and equilibrated with buffer A (50 
mM Tris/HCl, 10 mM MgCl2, 100 mM NaCl, 20 mM KCl, 1 mM β-mercaptoethanol, pH 
7.5).  A 10 ml gradient was created in the column from buffer A to buffer B (50 mM 
Tris/HCl, 10 mM MgCl2, 100 mM NaCl, 20 mM KCl, 5 mM β-mercaptoethanol, and 8 
M Urea, pH 7.5).  1 ml of inclusion bodies dissolved in buffer B was loaded in the 
column and pushed through by the Urea gradient at a rate of 0.5 ml/min.  Fractions were 
collected that contained refolded and separated proteins.   
 Alternate concentration methods were attempted before using a stir cell.  These 
included using a Centricon Plus-70 (Millipore) [65] centrifuge cartridges and Pierce 
SnakeSkin Dialysis Tubing [62] with polyvinylpyrolidone powder.  Both methods were 
based on the Rapid Dilution refolding method.  Using Amicon cartridges was rather 
simple.  The cartridge, Centricon Plus -70 ml, was equilibrated with either 10 mM Tris or 
1x PBS (sterile).  After equilibration, the refolded protein solution was added to the 
cartridges and spun at appropriate speed.  The cartridge cannot be spun faster than 3,000 
rpm as the force rendered the membrane useless and protein passed through and/or 
precipitated.  The same cartridge was used up to four times.  After the solution was 
concentrated down to a small enough level, 10- 50 ml, a cartridge that handled a smaller 
level of solution, the Pierce 7 ml iCON Concentrators previously mentioned, were used 
to concentrate down to less than 10 ml. 
 The second alternate method used the same type of dialysis tubing previously 
mentioned, Pierce SnakeSkin 3000 NMWC [62].  The refolded protein solution was 
added to the tubing and the tubing was tied, or clipped, so that no leakage occurred.  
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Polyvinylpyrolidone (Sigma) powder was spread over the tubing.  This powder slowly 
pulled the water out of the tubing, which concentrated the refolded solution.  The process 
was watched very carefully so that the tubing did not collapse and dry out.  Again, the 
process is stopped at an appropriate level, between 50- 100 ml, so that the previously 
mentioned Pierce concentrators could be used to finish the concentration.  The results of 























3.1 Sequencing Analysis of sCD16 Proteins 
 The wild type sCD16A and four of the sCD16 site-specific mutants were 
confirmed to have correct sequencing.  Sequencing analysis was performed on the protein 
samples by two different labs and the results were compared to the published wild type.  
The first laboratory is the Emory DNA Sequencing Facility and is part of the DNA Core 
Facility at Emory University.  The second laboratory is Tom Howards lab in the 
Pathology Wing of the Woodruff Memorial Research Building at Emory University.   
The mutants that had correct sequencing are sCD16A F176V, sCD16A G147D, CD16B 
NA2 V176F, and CD16B NA2 D147G (Table 1, Figure 12).  Genes without correct 
sequencing were not allowed to be expressed.  Table 1 shows the sequence locations of 
the site mutations for both CD16A and CD16B. 
 
Table 1.  Mutation sites at amino acid 147 and 176 of sCD16 A and B.  Letters in bold 
are the locations for the site specific mutations involved in this project.  Mutations cause 
the underlined letters to change between amino acids D and G at position 147 and 








Figure 12.  Cartoon depicting the locations of the amino acid mutations at position 147 
and 176 in both CD16A and CD16B.       
 
3.2 Soluble CD16 Expression Pathway Analysis 
 Two pathways were tested for optimal expression results, Invitrogens BL-21AI 
[49] and Stratagenes BL-21 RIPL [59].  Figure 10 shows as SDS-page with Western blot 
comparing the two pathways after expression and Inclusion Body treatment [1, 2, 54].  
BL-21 AI far outperformed BL-21 RIPL when expressing wild type sCD16A for 8 hours 
at 37° C at a starting Optical Density (600 nm) of 0.4.  Cell lysis and sonication treatment 
steps were the same as previously explained in the Materials and Methods section.  The 
primary antibody used in the Western blot was monoclonal 214.1, while the secondary 
antibody was goat-anti-mouse.  Exposure time was 30 seconds.  The Stratagene pathway 
was still used later in an attempt to obtain a higher expression yield with the sCD16B 




Figure 13.  Western Blot analysis on sCD16 induction pathways results after SDS-PAGE.  
Monoclonal 214.1 was the primary antibody.  Lane 1 is sCD16A expressed in the BL21-
AI pathway (Invitrogen).  Lane 2 is sCD16A expressed in the BL21 RIPL pathway 
(Stratagen).  Lane 3 contains CD16A-Ig complex.  Bio-Rad 12% Tris polyacrylamide gel 
and Bio-Rad nitrocellulose membrane were used.  
 
 
 Expression duration of the proteins and pre-induction initial conditions were 
tested and found to be optimal when 0.2% Arabinose and 1 mM IPTG are added to the 
bacterial culture when the solution is at 1.0 OD 600 nm and incubation length continues 
for 8 hours.  Figure 14A shows wild type sCD16A protein levels (SDS-PAGE and 
Western Blot) at various expression lengths, 4-8 hours.  8 hours outperformed the shorter 
incubation times for the wild type sCD16A.  Figure 14B shows the BL-21 AI pathway 
when transcription is both blocked and turned on. When Arabinose is added in the 
appropriate amount, the transcription pathway is turned on as the I2 inhibitor is blocked 






 The wild type sCD16A and the two sCD16A mutants (F176V and G147) all 
expressed quality inclusion bodies in the Invitrogen BL21-AI pathway.  All three were 
expressed at an OD 600 nm value of 1.0 with .2% Arabinose and 1 mM IPTG.  The two 
mutant proteins showed better inclusion bodies at 10 hour incubation rather than 8 hour.  
The two sCD16BNA2 mutants (D147G and V176F) did not express in the BL21-AI 
pathway at all.  Examples of their expression levels are in Figure 15.  Both sCD16B 
mutants were induced at multiple OD levels and were expressed for multiple durations.  
The figures show the lack of an appropriately sized band in the low 20 kD range.  The 
Stratagene BL21 RIPL pathway was then used on the two sCD16B mutants in an attempt 
to obtain the target protein expression.  However, this pathway did not produce superior 




     
 
Figure 14.  A, Western Blot analysis of SDS-PAGE.  Lane 1 contains CD16A-Ig.  Lanes 
2, 3, 4, and 5 contain sCD16A expressed in the BL21-AI pathway for 4, 5, 6, and 8 hours, 
respectively.  Protein expressed at a OD 600 nm value of 0.4 using 0.2% Arabinose and 1 






Figure 15.  A, sCD16BNA2 V176F inclusion bodies induced in BL21-AI pathway under 
different conditions.  Lanes 1-3 are induced at 1.0 OD 600 nm, while 4-6 are induced at 
1.5.  Lanes 1 and 4, 2 and 5, and 3 and 6 were induced for 8, 10, and 12 hours, 
respectively.  B, sCD16BNA2 D147G induced for 10 hours in the BL21-AI pathway at 
1.0 OD 600 nm with .2% L-Arabinose and 1 mM IPTG.  Lane 1 contains the inclusion 




    3.3 Soluble CD16 Inclusion Body Treatment Analysis 
  Two sonication methods were tested for the quality of the inclusion bodies that 
they produce.  The first was a method by Steinle, et al [1], which included a series of 
sonication steps with quick short bursts for durations of 30 seconds.  The second method, 
Altman et al [2], included longer durations of sonication, 90 seconds, and slightly 
different concentration of chemicals (Dnase I and lysozyme are slightly higher and 
MgCl2 is substituted for MgSO4) [1, 2].  The following figures (Figure 16) show the 
quality of the Inclusion Bodies and the supernatants of washing steps.  Altmans longer 
sonication steps showed a cleaner sample compared to Steinles method (Figure 16C).  
Figure 16C shows a sizeable target protein band in the low 20 kD range but has far too 
many non-target proteins in the Urea solution.  Figure 16 also shows a lack of target 
protein in the supernatants as the target protein is found in the inclusion bodies.  It also 
shows the effectiveness of the washing steps as the supernatants are much more clean 
later in the sonication steps as compared to the initial step. 
 Inclusion bodies dissolved in the Urea solution typically had a volume of 30 ml 
and a concentration between 20 mg/ml and 50 mg/ml.  The higher the percentage of the 
target protein compared to the whole of the inclusion bodies, the better the results of the 
subsequent refolding and purifying experiments [2, 54].  Figures 16A and 16B show 
quality, high ratio inclusion bodies, while Figure 16C shows poor inclusion bodies in 
which the target protein makes up a small percentage of the entire sample.  Three proteins 
provided quality inclusion bodies.  These proteins are wild type sCD16A, sCD16A GPI 
F176V, and sCD16A G147D (Figure 16A and 16B).  Two mutants, sCD16BNA2 D147G 
and sCD16NA2 F176V, never produced high quality, target protein rich inclusion bodies 







Figure 16.  A, inclusion bodies expressed at 1.0 OD 600nm for 8 hours after inducing 
with 0.2% Arabinose and 1 mM IPTG in the BL21-AI pathway.  Sonication steps 
included 90 second intervals of sonic treatment.  Lane 2 is wild type sCD16A and Lane 3 
is the sCD16A F176V mutant.  B, sCD16A G147D mutant expressed with the same 
conditions as part A.  Lane 1 is sCD16A G147D inclusion bodies, while Lanes 2 through 
5 are the sonication supernatants in order.  C, An example of a poor inclusion bodies 
sample.  Lane 1 is the poor inclusion body sample and Lanes 2 through 7 are the 
sonication supernatants.  All three gels were 12% Tris-Hcl (Bio-Rad) with 50 µl wells.  






3.4 Refolding Results of sCD16 Protein 
  The refolding experiments proved to be very difficult and time consuming.  At 
first the treated inclusion bodies were refolded by a stepwise dialysis method where the 
inclusion bodies were dissolved in an 8.5 M Urea solution and slowly dialyzed against a 
refolding buffer with a lower concentration of Urea each round (8.5, 6, 4, 2, 1, 0.5 M) 
until there was 0 M Urea [1].   At this point the proteins would be completely refolded 
and its buffer exchanged to an appropriate storage buffer.  This process failed at the level 
of 0.5 M Urea every time due to heavy precipitation [1].  Steinle and Li, et al., 
acknowledged that precipitation may occur after all protein has been dissolved and that 
they will be misfolded aggregates [1].  The experiment produces yields in the 2- 5% 
range, on average.  However, the precipitation occurred while refolding agents were still 
present and protein analysis showed minimal amounts of sCD16 in the solution.  The 
process took several weeks to complete, so after many failed attempts a new process was 
sought out.   
 Another refolding process that was attempted was to create a gradient refolding 
buffer that pushed the dissolved inclusion bodies through a size exclusion column made 
of Sephadex G- 50 packed beads [63, 64].  The inclusion bodies were loaded into the 
column and pushed through in the presence of a refolding buffer whose gradient went 
from 8.5 M Urea to 0 M Urea.  The beads would separate the proteins based on size and 
the gradient would refold the proteins.  Two sizes of Sephadex were tried, G-50 and G-
200.  The fractions collected showed that the sizes of the beads were incorrect as one size 
didnt separate the proteins (Figure 17) and the other size blocked the proteins from 
entering the bed.  Functional characterization showed that the proteins were not totally 
refolded properly.  Lastly, the amount of inclusion bodies put into the column was far too 
insufficient to obtain the necessary concentration level of 10 mg/ml (Figure 17).   
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Figure 17.  SDS-PAGE of refolded sCD16A wild type fractions from G-200 Sephadex 
size exclusion column with a Urea gradient.  Proteins were not separated well enough and 
are far too low in concentration to make a final refolded sCD16 solution of 10 mg/ml.  A 
Bio-Rad 12% Tris-HCl polyacrylamide gel was used with 25µl sample.  
  
 
 The third process was a Rapid Dilution Injection method [3].  Two injections of 
50 mg of inclusion bodies each are added to 1 L of stirring refolding buffer (.4 M L- 
Arginine, .1 M Tris, 2 mM EDTA, 5 mM glutathione reduced, .5 mM glutathione 
oxidized, .2 mM PMSF, pH 8.0) over two days time.  This process created the most 
controlled results and the best amount of properly refolded protein.  Figure 18 shows a 
coomassie blue stain of stir cell refolded sCD16A after SDS-PAGE.  The only variable in 
this process was the amount of solution the refolded buffer resides in.  The entire amount 
needed to be concentrated down to create a 10 mg/ml concentration.  Functional testing 
ensured that the protein was refolded properly.  Also, optimal concentration occurred 
when concentration immediately followed the refolding process without any delay.  A 
very low amount of aggregation would sometimes occur after the first day of refolding.  
This aggregation would be physically removed with a syringe before injecting the 
solution for a second time.  The refolding solution continued to stir at 4° C while the stir 
cell concentrated the first 300 ml of solution.    
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3.5 Concentration of Refolded sCD16 
 After choosing to continue with the Rapid Dilution Injections [3] to refold the 
sCD16 proteins, concentration methods were attempted that allowed the sCD16 proteins 
to reach a minimum of 10 mg/ml without causing precipitation.  It was also beneficial if 
the proteins can be washed to rid the solution of unwanted cellular proteins that may have 
been present in the inclusion bodies.  A dialysis bag method [1, 62] was used at first in 
which the refolded proteins in refolding buffer were put in SnakeSkin (Pierce) dialysis 
bags with a molecular weight cutoff of 10 kD and covered with polyvinylpyrolidone.  
This method concentrated 1 liter of buffer within 24 hours under very careful visual 
supervision as polyvinylpyrolidone levels needed to be maintained.  However, the 
powder caused the dialysis bags to dry out and stiffen, if allowed to continue for too long, 
and target protein recovery from the bags was often difficult.  Careful washing of the 
inside of the tubing occurred with little protein recovery.  SDS-PAGE would show only 
the slightest trace of refolded protein.  In attempt to concentrate the solution to 10 mg/ml, 
the bags ended up too flat and eventually dried out.  Typical concentration was about 30 
to 1 ratio of pre-volume to post volume.    
 A second method entailed using a Centricon Plus-70 Concentrator tube with high 
volume capacity [65].  70 ml could be concentrated per container with the Beckman rotor 
holding four centrifuge containers at once.  The Centricon tubes yielded an increased 
concentration of 50 to 1.  The containers would still have to be used multiple times, 
which caused precipitation of the proteins in the concentrator filters membrane.  This 
damaged the membranes functioning ability and the ability to effectively use this 
method.  Centrifugal filter devices were still not an ideal solution due to protein damage 
from having a low volume capacity and a large volume needing to be concentrated.        
 Using a 350 ml Amicon stir cell from Millipore was the eventual solution [4, 5].  
The entire 1 liter of solution could be concentrated in 3- 7 days.  The Amicon stir cell 
used a 10 kD NMWL Ultracel Amicon UltrafiltrationDisc membrane (Millipore) and a 
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nitrogen gas tank that pushed the stirring solution through this membrane.  Figure 18 
shows SDS-PAGE analysis (Pierce 12% Tris gel, 50 µl well, 25 µl sample) of target 
protein and the increased concentration and purity after using a stir cell.  Figure 18A 
contains SDS-PAGE samples of wild type sCD16A and sCD16A F176V from the initial 
concentrations by a stir cell and by subsequent concentrations by iCON concentrators.  
Figure 18B shows the same thing only with sCD16A G147D.  The effectiveness of the 
dual concentration is quite clear.   
 
            
 
Figure 18.  A, SDS-PAGE analysis on refolded sCD16 proteins.  Lane 1 is refolded wild 
type sCD16A protein and Lane 2 is refolded sCD16A F176V mutant protein.  Both 
samples taken from the post stir cell concentration solution.  Lanes 3 and 4 are the same 
wild type and mutant protein after a second concentration in Pierce iCON concentrators.  
B, The same process as A, only with refolded sCD16A G147D mutant.    
 
 The other positives of using the stir cell to concentrate the solution were a lack of 
precipitation, the removal of most of the unwanted, excess proteins, and the ability to 
wash the proteins in the eventual storage buffer, 10 mM Tris.  The refolding buffer was 
concentrated to a level between 20-50 ml.  It was very rare for any aggregation to occur 
and physical removal by way of a syringe would rid this precipitation so that the 
membrane would not become clogged.  A series of washings in 10 mM Tris occurred 
upon completion of concentration.  A final volume between 20-40 ml was taken out of 
the stir cell with careful washing of the membrane itself to collect any proteins residing 
on its surface.  Additional concentration experiments took place in 15 ml Falcon tubes 
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with Pierce 7ml iCON Concentrator membranes [60].  Figure 18, above, shows a second 
concentration of the refolded protein to approximately 10 mg/ml.  The second 
concentration allowed for fine tuning of the concentration after Micro BCA (Pierce) 
protein estimation so that a level of 10 mg/ml was reached [61].  It also allowed for 
further washing of the solution.  In most occurrences the protein purity was well above 
90-95% and crystal trials began soon after, as long as functional characteristics were 
within range [44].   
 In the case of purity, a coomassie blue stain and silver stain were needed to verify 
that the protein solution was clean (greater than 90-95%) [54]. However, SDS-PAGE 
with a protein in Tris buffer could show results that looked like trace proteins in a silver 
stain [54].  Affinity chromatography with CLB coated Sepharose (GE Healthcare) beads 
[4, 5, 54] or an automated S-300 size exclusion column (Bio-Rad) were attempted in 
order to purify sCD16 proteins.  However, every attempt made to use the affinity column 
ended with a clogged pre-column (plain Sepharose beads).  The automated column had 8 
ml fractions, which were too large for this process.  A large peak on the OD readout was 
present at the correct location for sCD16 and SDS-PAGE analysis showed this fraction in 
Figure 19.  The fraction did not provide a clean enough sample and was low in 
concentration due to the limit of a 2.5 ml injection of protein, which was not allowed to 
be made of high concentration for fear of clogging the column.  This problem was never 
resolved but the majority of refolded proteins were already pure enough to warrant 




Figure 19.  SDS-PAGE of S-300 fraction contained sCD16A wild type.   
 
 The storage buffer of the refolded protein also played an important role.  Soluble 
protein exhibited precipitation in certain buffers and temperatures [45].  At first protein 
was stored in 1x sterile PBS buffer.  There was no precipitation in this buffer, but it was 
not an ideal buffer for growing crystals [45].  A second buffer, sterile Tris buffer, was 
better suited for making crystals but showed precipitation with certain environment 
changes.  If kept at 4° C for too long, some protein would precipitate and drop the 
concentration below the target 10 mg/ml.  Also, during crystal trials, the protein was 
reported to be sensitive to sudden thawing.  Two Tris buffers were tested, 100 mM and 
10 mM.  The protein seemed to be more stable with the 10 mM and crystals grew better 
when in the 10 mM Tris buffer.  Care has been taken to store the refolded solution at 
several temperatures, -70° C, -20° C, and 4° C, to record which gave the best results.  As 
crystals can take months to grow, results will not be available for some time. 
 
3.6 Functional Testing of sCD16 Proteins 
 After the refolding process, care was taken to ensue that sCD16 proteins were 
refolded correctly by testing the protein functioning ability.  Recent experiments by Dr. 
Selvarajs laboratory and Dr. Zhus has established binding properties of CD16A and the 
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site specific mutants expressed in a eukaryotic pathway (Figure 21).  Sandwich ELISA 
(Enzyme- linked Immunosorbant Assay) studies were carried out on wild type sCD16A 
and two mutants, sCD16A F176V and sCD16A G147D (Figure 20).  These proteins were 
coated onto ELISA plates overnight, blocked with ELISA buffer (1x PBS, 1 mM EDTA, 
1% FCS, 0.5% Tween), bound with Immune Complex, bound with 2ry antibody (Goat-
anti-mouse-HRP), and developed with Amersham TMB Developer (GE Healthcare).  
Plates were read at 415 nm in an ELISA reader (Bio-Rad) and compared to positive 
control (CD16A-Ig) and negative control.  The ELISA results were comparable to 
separate studies performed in Dr. Selvarajs lab dealing with the same CD16 mutants 
expressed in a eukaryotic pathway, which indicated that these three proteins have 
refolded properly.  According to the purity, functional data, and the concentration, 
crystals could now be made for the wild type sCD16A and the two site specific sCD16A 
mutants (F176V and G147D).   
 
   
 
Figure 20.  Results of Sandwich ELISA.  See text for explanation of experiment.  









 4.1 Current status and errors in the creation of sCD16 gene and sequencing 
 Three soluble CD16 proteins (sCD16A wild type, sCD16A F176V, and sCD16A 
G147D) were expressed to an optimal level, refolded properly, and were of sufficient 
purity to have begun crystal trials.  These trials are currently ongoing as crystals have 
been growing and data is being collected.  The mutant sCD16B proteins have not been 
expressed and refolded to the appropriate level for several reasons.  Two of the proteins 
(sCD16BNA1 D147G and sCD16BNA1 V176F) never made it through the sequencing 
analysis after introducing the extracellular gene into the new pET 21a+ vector.  
  The extracellular portions of wild type CD16A and CD16B are approximately 
97% identical and the wild type NA1 and NA2 alleles of CD16B are 95% homologous [24].  
Therefore, it is an unknown reason as to why the sCD16BNA1 mutants had incorrect 
sequences compared to the other mutants, even after several repetitions of the 
extracellular gene construction.  Sequencing experiments were conducted by two 
different labs and analyzed using DNA sequencing software (Jellyfish).  Sondermann, et 
al. [4], and Zhang, et al. [5], were able to obtain the extracellular portion of CD16B 
through similar steps in each of their experiments and the extracellular sequence cutoff of 
the gene was very similar to the previous studies, although the vectors were slightly 
different.  Possible reasons for the poor sequencing were errors in the PCR experiment, 
including the primers binding to incorrect areas and high temperature heating causing 
adverse effects, and the digestion of more than just the ends of the gene before ligation.  
However, due to the extreme similarity between CD16BNA1 and CD16BNA2, this is highly 
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unlikely.  One other issue with the creation of the extracellular portion of the gene was 
the lack of a His- tag [67, 70].  An attempt to insert this sequence was thwarted by the 
creation of an unwanted restriction enzyme site which interfered in the process of ligating 
the gene into our chosen vector.  The restriction sites needed for the His-tag would digest 
the CD16 gene in multiple locations and, therefore, could not be used.     
 The last two proteins (sCD16BNA2 V176F and sCD16BNA2 D147G) never 
expressed to a high enough level during induction experiments [4, 5] despite showing 
correct sequencing.  Induction experiments were conducted using both the BL-21 AI 
pathway (Invitrogen) [49] and the BL-21 RIPL pathway (Stratagene) [59] to no avail.  
Neither showed any protein with the AI pathway after being expressed dozens of times 
with various durations (Figure 15) and starting Optical Densities (600 nm).  The second 
pathway produced very minimal results with sCD16BNA2 V176F when induced for 12 
hours starting at an OD 600 nm value of 1.0.  However, the protein was no more than 
15% of the total Inclusion Bodies and the expression hasnt been reproduced.  Refolding 
experiments could not take place from these results as the yield would be extremely low 
and the sample would be far too impure [1, 2, 4, 5, 70].  Expressing quality inclusion 
bodies made primarily of the target protein has proven to be a difficult process [1, 2, 44, 
67, 70].  Usually, changing the starting conditions or the expression pathway will resolve 
the issue [1, 2, 44].  Mutations in the protein could make it more susceptible to bacterial 
processes that are not present in human cells that can result in degradation [44, 70].  This 
can be especially so with expression durations lasting more than 12 hours, which would 
already be harmful for normal proteins due to degradation.    
4.2 Functional Testing of the soluble sCD16 Protein 
 A separate study in Dr. Selvarajs lab, conducted by Ravichondran has shown that 
all six mutants involved in this study have been expressed in CHO-K1 cells and yielded 
active proteins.  Figures 21 and 22 show these results.  This experiment was conducted 
 49
by transfecting CHO-K1 cells with a mammalian expression vector, which contained the 
mutant CD16 genes, selecting cells by panning and then analyzing the expression by 
using flow cytometry.  The experiments suggested that the CD16 mutants had various 
levels of avidity for the immune complex but were all unable to bind to monomeric IgG.  
The wild type sCD16A and the two sCD16A site specific mutant (F176V, G147D) 
proteins that have been expressed showed functioning characteristics in the Sandwich 
ELISA binding studies comparable to the results put forth by this study.  Although not a 
bacterial expression pathway, it still shows that all the mutants can be expressed in an 
active state in a eukaryotic pathway.  This, along with Sondermann et al. [4] and Zhang et 
al. [5] success, show that further changes in the expression pathway, and more 




Figure 21.  Rosetting assay for CD16 Mutants.  Rosetting results (Figure 19) show 
binding activity of wild type CD16A and the six site specific CD16 mutants expressed in 





Figure 22.  Rosetting results for Figure 18.  A, Results show expression of CD16 mutants 
on CHO-K1 cells.  B, Results show CD16A does not bind to monomeric IgG. 
 
4.3 Expression of sCD16 
 
 The wild type sCD16A and the two sCD16A mutants (F176V and G147D) 
expressed very well (Figure 16) in the BL-21 AI pathway provided by Invitrogen [49].  
This pathway was designed specifically for pET vectors (Novagen) and utilized L-
Arabinose to aide IPTG in turning on the transcription mechanism.  The vector, pET 
21a+, was under the control of the Lac operon and used IPTG to release the repressor of 
transcription to allow for production of the protein (Figure 14B).  The AI pathway 
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involved a second control point, the araBAD promoter, which tightly regulated 
expression in this particular vector [49].  L- Arabinose turned this promoter on allowing 
for IPTG to induce the target protein. Ideal conditions for the expression of the sCD16A 
proteins included growing seed cells for 16 hours at 32° C prior to induction [54].  Next, 
the protein was induced by adding 0.2% L-Arabinose and 1 mM IPTG at 1.0 OD at 
600nm and continued incubation for 7 to 10 hours.  Standard induction began at 0.4 OD 
at 600 nm and would continue for approximately 6 hours [1].  This induced the protein 
when cell growth reached the log phase and continued for a duration of time long enough 
to accumulate protein but short enough to prevent proteolytic degradation [45].  
However, this did not produce the best yield of the target protein in the inclusion bodies.  
Better yields were typically found with a slightly higher starting cell concentration due to 
the higher number of cells initially producing the target protein [1, 2].   
 Optimal induction times tended to vary depending on the efficiency of the 
pathway, the protease buildup, and the production of other cellular proteins [1, 45].  In 
our case, the target protein was produced at six hours induction time but didnt develop 
optimal inclusion bodies until 8-10 hours (Figure 14A).  Optimal inclusion bodies were 
made up of a very high percentage of target protein, which in turn gave the best refolding 
results [1, 2].  The use of the second pathway, BL-21 RIPL (Stratagene), was to supply 
the expression environment with extra amino acids that may be in demand in a bacterial 
expression pathway, limiting the quality of the inclusion bodies produced [45].  The 
second pathway produced worse results than the Invitrogen pathway in all three sCD16A 
proteins (wild type, F176V and G147D mutants).  It is possible that the second control 
point in the AI pathway was able to tightly regulate all cellular proteins until the L-
Arabinose was added, providing a higher yield of target proteins.  Also, the second 




4.4 Refolding of sCD16 From Dissolved Inclusion Bodies 
 
 After the optimal inclusion bodies were obtained, refolding experiments were 
performed.  Several methods of refolding were used with varying effectiveness [67, 70].  
The first method involved using Pierce SnakeSkin [1, 62] dialysis tubing to bring the 
Urea out of the dissolved inclusion bodies very slowly and thus forcing the protein to 
refold in a steady fashion.  This slow process ideally produces a higher yield of refolded 
target protein by keeping total control of the process while at the same time keeping the 
volume low [1, 2, 45, 70].  However, there was significant precipitation as the solution 
crept closer to 0 M Urea.  When using the step down method, there is usually a critical 
refolding point and if it is not reached, or if the process occurs too quickly, the proteins 
will form aggregates or turn into inclusion bodies again and precipitate due to the low 
amount of Urea [1].  This refolding point is different for every protein.  Also, the amount 
of refolding buffer used to dilute the Urea and drive the folding was 5 liters.  According 
to refolding protocols [1, 2, 3, 45, 70], a larger amount of solution was recommended as 
the additives in the refolding solution have a great effect on the dissolved proteins [46] 
and with a high starting concentration of those proteins, a greater amount of refolding 
buffer could only help.  However, this increases the scale of the experiment to a much 
larger size.  Using this refolding method was very time consuming and with continued 
precipitation, we felt we would get better results using smaller portions of the dissolved 
inclusion bodies and forcing the protein to refold quickly [2, 3].     
 A second refolding method involved a size exclusion Sephadex column and a 
Urea gradient, which forced refolding, separated the proteins, and removed the Urea [70].  
This process is becoming more popular but is still tough to accomplish [70].  The size of 
the Sephadex beads needed to be changed to G-75 or G100 to allow the target protein to 
pass through the column while blocking out larger proteins.  Even if these changes would 
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work, it would still not provide the necessary final concentration as the scale would be 
too small [4, 5].  Figure 17 shows some of the eluted fractions from the column.      
 The refolding method that produced the best results was the rapid dilution method 
[2, 3, 45].  These results showed that the refolded sCD16 proteins (wild type and mutants 
F176V, G147D) exhibited similar binding to the previously mentioned study from our lab 
(Ravichondran).  This confirmed the active state of a correctly refolded protein.  After 
concentrating to 10 mg/ml using an Amicon stir cell (Millipore), the protein purity was 
checked by SDS-PAGE and shown to be greater than 95% purity in the gels (Figure 13).  
This was adequate enough to start producing crystals from wild type sCD16A, sCD16A 
F176V, and sCD16A G147D.  Some samples showed residual proteins upon 
concentration.  Washing the solution several times and readjusting the concentration 
usually rid the solution of most of these unwanted trace proteins as they passed through 
the filter or precipitated in the filter and were discarded after centrifugation (Figure 23).  
Some target protein was also lost in this process, which called for a readjustment in 
concentration.  In the instance that washing did not work, the sample was discarded.  All 
affinity column purifications attempted, including CLB affinity chromatography, failed to 
produce any positive results as the protein never make it through the column.  The lack of 
a His-tag was the most likely cause of this problem [47].  Several types and sizes of 
columns were used but none produced adequate results.  Although there was no 
chromatography purification, crystal trials still produced excellent results due to a high 
concentration of pure protein shown by the SDS-PAGE on the wild type sCD16A and the 
two mutant sCD16A proteins (F176V and G147D), shown in Figure 18.   
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Figure 23.  SDS-PAGE washing results of refolded wild type sCD16A.  A, One washing 
step with 10 mM Tris buffer to help rid solution of unwanted protein.  Lanes 1 and 3 are 
the same (pre-washing), as are Lanes 2 and 4 (post washing).  Lanes 3 and 4 are is the 
negative representation to aid in viewing the bands.  B, A second example of washing to 
rid solution of trace proteins.       
 
 
4.5 Future Work and Conclusions  
 Recommended future work after the expression and refolding of the three 
sCD16A proteins (wild type, F176V, and G147D) includes several experiments.  First, 
the continuation of the crystal trials for the three proteins already expressed and refolded.  
Current efforts by Dr. Zhus lab (Wei Chen and Chris Curry) include using diffraction 
data received from sCD16A F176V crystals to solve the sCD16A F176V structure using 
molecular replacement with sCD16BNA2 as a search model.  Crystals have grown in four 
different conditions.  The first was 0.1 M Citric Acid (pH 3.5) and 2.0 M Ammonium 
Sulfate.  The second was 0.1 M HEPES (pH 7.5) and 1.4 M tri-Sodium Citrate Dihydrate.  
The third was 3.5 M Sodium Formate (pH 7.0).  And fourth was 60% v/v Tacsimate (pH 
7.0).  Four optimized conditions, all at room temperature, produced diffraction data.  The 
first was 2.2 M Ammonium Sulfate and 0.1 M Citric Acid (pH 2.5).  The second was 3.1 
M Sodium Formate (pH 6.5).  The third and fourth were 3.9 and 3.7 M Sodium Formate 
(pH 7.0).  The crystals were diffracted by Annie Heroux at the National Synchrotron 
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Light Source to a 1.6 Å resolution.  Ongoing efforts also include growing crystals for 
wild type sCD16A and the sCD16A G147D mutant. 
 The expression of sCD16BNA1 D147G, sCD16NA1 V176F, sCD16BNA2 D147G, 
and sCD16BNA2 V176F mutants should include a different vector.  A different pET vector 
(pET 28) may be the best place to start since the BL21- AI conditions have been 
established.  The inclusion of a His-tag is recommended, which would increase the 
effectiveness of affinity chromatography purification.  It is also recommended that the 
same sonication, refolding, and concentration protocols be followed initially as they too 
have been established.  Also of significance, are attempts at purifying target proteins 
while still in the dissolved inclusion bodies state before refolding [74].  This may be a 
method to speed up the current process of sCD16A proteins (wild type, F176V, and 
G147D) that are still lacking the His-tag sequence.   
     In conclusion, the study of the FcR family, and more specifically the FcR-Ig 
interaction, is of great significance to immunology and autoimmune disease research.  
Future drug designs to fight disease and the alleviation of specific allergic reactions need 
functional and structural data.  CD16 structural data, obtained from the proteins 
expressed in this project, can be used to develop methods of altering its Ig interactions to 
help alleviate symptoms or to prevent them from starting.  It also lends information to the 
entire FcR family to possibly develop a method that has an effect on all members due to 
the significant homology of the extracellular domains.  With the continued improvement 
of crystallization technology, better structural models can be developed, which will aid in 
the understanding of FcRs.  Improvements in soluble protein expression through 
prokaryotic pathways can make this process all the more effective.  With time, the wild 
type sCD16A structure will be solved from this project.   Then, matching the mutant data 
with the previously proposed models and the ongoing mechanical studies will give a 
more complete picture of the CD16 receptor and possibly lead to future breakthroughs 
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